

# Rachna T Shroff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7212637/publications.pdf>

Version: 2024-02-01

75  
papers

6,948  
citations

136950  
32  
h-index

91884  
69  
g-index

76  
all docs

76  
docs citations

76  
times ranked

7815  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review. Hepatobiliary Surgery and Nutrition, 2022, 11, 253-266.	1.5	8
2	The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology, 2022, 75, 297-308.	7.3	32
3	Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH1-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precision Oncology, 2022, 6, e2100197.	3.0	10
4	Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. European Journal of Cancer, 2022, 172, 65-75.	2.8	24
5	Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precision Oncology, 2022, , .	3.0	19
6	Precision Medicine in Biliary Tract Cancer. Journal of Clinical Oncology, 2022, 40, 2716-2734.	1.6	12
7	The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs. Expert Opinion on Investigational Drugs, 2021, 30, 281-284.	4.1	7
8	Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Journal of Gastrointestinal Oncology, 2021, 12, 2268-2274.	1.4	0
9	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. JAMA Oncology, 2021, 7, 1669.	7.1	194
10	Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nature Medicine, 2021, 27, 2002-2011.	30.7	167
11	Current and emerging therapies for advanced biliary tract cancers. The Lancet Gastroenterology and Hepatology, 2021, 6, 956-969.	8.1	81
12	Moving the Needle Forward With Locoregional Treatment in Unresectable Cholangiocarcinoma—The Jury Is Still Out. JAMA Oncology, 2020, 6, 29.	7.1	7
13	Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 1385-1394.	7.0	31
14	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 4317-4345.	1.6	350
15	What is the role of PARP inhibitors in pancreatic cancer?. Expert Review of Anticancer Therapy, 2020, 20, 913-918.	2.4	3
16	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 796-807.	10.7	620
17	Moving Beyond Chemotherapy for Pancreaticobiliary Tumors: Targeted and Immunotherapy Strategies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, , e333-e343.	3.8	1
18	Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Medicine, 2020, 9, 5406-5415.	2.8	9

#	ARTICLE	IF	CITATIONS
19	Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. Journal of Gastrointestinal Oncology, 2020, 11, 55-60.	1.4	5
20	Pancreatic cancer. Lancet, The, 2020, 395, 2008-2020.	13.7	1,376
21	Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. Future Oncology, 2020, 16, 2375-2384.	2.4	62
22	Biliary tract cancers: systemic therapy for advanced disease. Chinese Clinical Oncology, 2020, 9, 5-5.	1.2	7
23	Charging forward in locally advanced pancreatic cancer. The Lancet Gastroenterology and Hepatology, 2020, 5, 234-236.	8.1	3
24	Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology, 2020, 20, 501-504.	1.1	31
25	Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers. World Journal of Gastrointestinal Oncology, 2020, 12, 83-91.	2.0	1
26	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. The Lancet Gastroenterology and Hepatology, 2019, 4, 711-720.	8.1	161
27	Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers. JAMA Oncology, 2019, 5, 824.	7.1	335
28	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 1015-1027.	1.6	301
29	First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 619-627.	1.5	8
30	Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).. Journal of Clinical Oncology, 2019, 37, 4087-4087.	1.6	42
31	Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. World Journal of Gastrointestinal Oncology, 2019, 11, 866-876.	2.0	13
32	Emerging Targeted and Immunotherapies in Cholangiocarcinoma. Oncology & Hematology Review, 2019, 15, 71.	0.2	1
33	Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist, 2018, 23, 277-e26.	3.7	34
34	Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. The Lancet Gastroenterology and Hepatology, 2018, 3, 337-348.	8.1	189
35	A Case Report—Stevens-Johnson Syndrome as an Adverse Effect of Capecitabine. Journal of Gastrointestinal Cancer, 2018, 49, 349-350.	1.3	6
36	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. JCO Precision Oncology, 2018, 2, 1-12.	3.0	86

#	ARTICLE	IF	CITATIONS
37	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	1.6	524
38	Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. <i>Cancer Medicine</i> , 2018, 7, 4880-4892.	2.8	23
39	Tu1402 COMPARISON OF THE PERFORMANCE OF COVERED METAL STENTS AND UNCOVERED METAL STENTS IN THE MANAGEMENT OF MALIGNANT BILIARY STRICTURES (MBO) IN 1012 PATIENTS.. <i>Gastrointestinal Endoscopy</i> , 2018, 87, AB580.	1.0	0
40	Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 71.	17.0	30
41	A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5883-5894.	7.0	76
42	The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. <i>British Journal of Cancer</i> , 2017, 116, 1402-1407.	6.4	54
43	Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. <i>Oncologist</i> , 2017, 22, 804-810.	3.7	91
44	Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. <i>Cancer</i> , 2017, 123, 1354-1362.	4.1	37
45	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2017, 152, 1048.	4.3	82
46	Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. <i>Annals of Surgical Oncology</i> , 2017, 24, 2031-2039.	1.5	30
47	Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. <i>Cancer</i> , 2017, 123, 1011-1017.	4.1	45
48	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 164-174.	1.7	124
49	Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 347-351.	1.4	30
50	Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4076-4076.	1.6	8
51	Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4086-4086.	1.6	8
52	Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4125-4125.	1.6	10
53	Clinical features and tumor mutational profile of younger versus older patients with cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 240-240.	1.6	0
54	Early obesity and risk of cholangiocarcinoma in the United States.. <i>Journal of Clinical Oncology</i> , 2017, 35, 239-239.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Phase II study of panitumumab in KRAS wild-type metastatic adenocarcinoma of the small bowel or ampulla of vater.. Journal of Clinical Oncology, 2017, 35, e15799-e15799.	1.6	1
56	Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations.. Journal of Clinical Oncology, 2017, 35, 11609-11609.	1.6	0
57	Characterization of germline genomic alterations in familial pancreas cancer.. Journal of Clinical Oncology, 2017, 35, 4116-4116.	1.6	2
58	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget, 2016, 7, 67495-67506.	1.8	42
59	BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype. Journal of Gastrointestinal Oncology, 2016, 7, 556-561.	1.4	20
60	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer, 2016, 122, 2671-2679.	4.1	49
61	Nextâ€generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer, 2016, 122, 3657-3666.	4.1	41
62	Biliary cancer: Utility of nextâ€generation sequencing for clinical management. Cancer, 2016, 122, 3838-3847.	4.1	289
63	Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Journal of Gastrointestinal Surgery, 2016, 20, 1975-1985.	1.7	42
64	Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. Journal of Clinical Oncology, 2016, 34, 219-226.	1.6	242
65	Consensus Conference on Gallbladder Cancer. Hpb, 2015, 17, 664-665.	0.3	5
66	The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Annals of Surgical Oncology, 2015, 22, 1221-1228.	1.5	44
67	HER2/neu-directed therapy for biliary tract cancer. Journal of Hematology and Oncology, 2015, 8, 58.	17.0	191
68	Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer. Indian Journal of Surgery, 2015, 77, 403-408.	0.3	2
69	Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2015, 76, 489-498.	2.3	59
70	Underuse of surgical resection among elderly patients with early-stage pancreatic cancer. Surgery, 2015, 158, 1226-1234.	1.9	31
71	Does IGF1R inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 307-313.	7.3	21
72	Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications. PLoS ONE, 2014, 9, e115383.	2.5	362

#	ARTICLE	IF	CITATIONS
73	Second-line systemic treatment for advanced cholangiocarcinoma. Journal of Gastrointestinal Oncology, 2014, 5, 408-13.	1.4	34
74	The Expression of PTEN Is Associated With Improved Prognosis in Patients With Ampullary Adenocarcinoma After Pancreaticoduodenectomy. Archives of Pathology and Laboratory Medicine, 2013, 137, 1619-1626.	2.5	14
75	Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE. Blood, 2013, 122, 580-580.	1.4	27